Literature DB >> 33598927

Pharmacokinetics of tolfenamic acid after different administration routes in geese (Anser cygnoides).

Erdinc Turk1, Ibrahim Ozan Tekeli1, Duygu Durna Corum2, Orhan Corum2, Fatih Sakin1, Kamil Uney3.   

Abstract

The pharmacokinetics and bioavailability of tolfenamic acid were determined in geese (Anser cygnoides) following intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral administrations at 2 mg/kg dose. In this study, eight healthy geese (3.5 ± 0.5 kg) were used. The study was performed in four periods according to a crossover design with a 15-day washout period between two administrations. The plasma concentrations of tolfenamic acid were analyzed using HPLC-UV, and pharmacokinetic parameters were calculated by noncompartmental analysis. The elimination half-life was 1.73, 2.51, 2.34, and 2.31 hr for IV, IM, SC, and oral routes, respectively. The volume of distribution at steady state and total clearance after IV administration were 0.25 L/kg and 0.16 L hr-1  kg-1 , respectively. The peak plasma concentrations of tolfenamic acid after IM, SC, and oral administrations were 4.89, 2.94, and 2.92 μg/ml at 0.25, 0.75, and 1 hr, respectively. The bioavailability was 87.91, 77.87, and 76.03% for the IM, SC, and oral routes, respectively. Tolfenamic acid, which exhibits the good bioavailability and plasma concentration following IM, SC, and oral administrations at 2 mg/kg dose, may be useful in the treatment of inflammatory disease conditions in geese.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  bioavailability; geese; pharmacokinetics; tolfenamic acid

Mesh:

Substances:

Year:  2021        PMID: 33598927     DOI: 10.1111/jvp.12956

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  1 in total

1.  Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock.

Authors:  Kamil Uney; Duygu Durna Corum; Ertugrul Terzi; Orhan Corum
Journal:  Pharmaceutics       Date:  2021-06-30       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.